Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mehta

Showing results (1121-1130 of 1,216) with videos related to

Pageof 122
Sort By:
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO groupNancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, et al.
JAMA Oncology|November 29, 2016
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)Paul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Designing Clinical Trials for Combination Immunotherapy: A Framework for GlioblastomaKirit Singh, Kristen A Batich, Patrick Y Wen, et al.
JCO Oncology Practice|May 11, 2022
Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series AnalysisNahomy Ledesma Vicioso, Diana Lin, Daniel R Gomez, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain MetastasesPaul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2025
Dual Immune Check Point Blockade in <i>MGMT</i>-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical TrialAndrew B Lassman, Mei-Yin C Polley, Fabio M Iwamoto, et al.
Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.
Pageof 122

Showing results (1121-1130 of 1,216) with videos related to

Sort By:
Pageof 122
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO groupNancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, et al.
JAMA Oncology|November 29, 2016
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)Paul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Designing Clinical Trials for Combination Immunotherapy: A Framework for GlioblastomaKirit Singh, Kristen A Batich, Patrick Y Wen, et al.
JCO Oncology Practice|May 11, 2022
Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series AnalysisNahomy Ledesma Vicioso, Diana Lin, Daniel R Gomez, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain MetastasesPaul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2025
Dual Immune Check Point Blockade in <i>MGMT</i>-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical TrialAndrew B Lassman, Mei-Yin C Polley, Fabio M Iwamoto, et al.
Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.
Pageof 122